274 results on '"Reed, Eddie"'
Search Results
2. Thalidomide : A Prodrug That Inhibits Angiogenesis
3. Platinum-DNA Adducts in Leukocyte DNA Correlate with Disease Response in Ovarian Cancer Patients Receiving Platinum-Based Chemotherapy
4. Biological Impact of Small Air Ions
5. Cisplatin-DNA Damage and Repair in Peripheral Blood Leukocytes in Vivo and in Vitro
6. Platinum Drug-DNA Interactions in Human Tissues Measured by Cisplatin-DNA Enzyme-Linked Immunosorbent Assay and Atomic Absorbance Spectroscopy
7. Polyclonal Antibodies to Quantitate Cis-Diamminedichloroplatinum(II)-DNA Adducts in Cancer Patients and Animal Models
8. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1–7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy
9. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells
10. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs
11. CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival
12. Colorectal Cancer Screening Practices in Alabama: A Survey of Primary Care Physicians
13. Duration of Cisplatin Excretion in Breast Milk
14. Vascular endothelium summary statement III: Cancer prevention and control
15. Vascular endothelium summary statement VI: Research directions for the 21st century
16. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer
17. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
18. Suramin's Development: What Did we Learn?
19. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines
20. An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function
21. Myb overexpression overrides androgen depletion–induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance
22. Enhancing Response Rates in Physician Surveys: The Limited Utility of Electronic Options
23. Pharmacokinetics and Relative Bioavailability of Carboxyamido-Triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters
24. Evaluation of Cisplatin in Combination with β-Elemene as a Regimen for Prostate Cancer Chemotherapy
25. Antineoplastic effect of β-elemene on prostate cancer cells and other types of solid tumour cells
26. Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer
27. Nucleotide excision repair and anti-cancer chemotherapy
28. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells
29. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response
30. Irofulven induces replication-dependent CHK2 activation related to p53 status
31. Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas
32. A Preliminary Risk-Benefit Assessment of Paclitaxel
33. ERCC1 Measurements in Clinical Oncology
34. Foreword: Promoting the Use of Registry-Based National Cancer Surveillance Data for Colorectal Cancer Prevention and Control
35. MZF1 possesses a repressively regulatory function in ERCC1 expression
36. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
37. Phase II Trial of Carboxyamidotriazole in Patients With Relapsed Epithelial Ovarian Cancer
38. Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies
39. A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer
40. Drug-Induced Lupus Associated With COL-3: Report of 3 Cases
41. Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
42. Autologous Stem-Cell Transplantation in Ovarian Cancer: Is More Better?
43. Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis
44. PRELIMINARY PHARMACOKINETICS (PK) OF COL-3, A MATRIX METALLOPROTEINASE (MMP) INHIBITOR
45. Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent Glioma
46. Cutaneous manifestations of taxol® therapy
47. Pharmacokinetics of thalidomide in an elderly prostate cancer population.: 56E.
48. Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.: 55E.
49. Preclinical and clinical pharmacokinetics of COL-3.: 54.
50. 59. An assessment of the effect of food on the single dose oral absorption and pharmacokinetics of micronized carboxyamido-triazole in cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.